LARIMAR THERAPEUTICS, INC. — Operating Income by Fiscal Year
14 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/452f25bb-5c06-4b70-94f4-fc3356f24d13/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-172.5M | 2025-01-01 – 2025-12-31 | evidence 0001193125-26-115878 |
| FY 2024 | $-90.9M | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-043925 |
| FY 2023 | $-41.8M | 2023-01-01 – 2023-12-31 | evidence 0000950170-24-031529 |
| FY 2022 | $-36.5M | 2022-01-01 – 2022-12-31 | evidence 0000950170-23-007855 |
| FY 2021 | $-50.5M | 2021-01-01 – 2021-12-31 | evidence 0000950170-22-004637 |
| FY 2020 | $-42.8M | 2020-01-01 – 2020-12-31 | evidence 0001564590-21-011003 |
| FY 2019 | $-23.2M | 2019-01-01 – 2019-12-31 | evidence 0001564590-21-011003 |
| FY 2018 | $-61.1M | 2018-01-01 – 2018-12-31 | evidence 0001564590-19-007863 |
| FY 2017 | $-53.0M | 2017-01-01 – 2017-12-31 | evidence 0001193125-18-077456 |
| FY 2016 | $-58.2M | 2016-01-01 – 2016-12-31 | evidence 0001193125-17-078784 |
| FY 2015 | $-73.8M | 2015-01-01 – 2015-12-31 | evidence 0001193125-16-505173 |
| FY 2014 | $-35.5M | 2014-01-01 – 2014-12-31 | evidence 0001193125-15-103624 |
| FY 2013 | $-13.8M | 2013-01-01 – 2013-12-31 | evidence 0001193125-15-103624 |
| FY 2012 | $-13.8M | 2012-01-01 – 2012-12-31 | evidence 0001193125-15-103624 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
LARIMAR THERAPEUTICS, INC. — all facts · Revenue · Net Income